Literature DB >> 20390427

Involvement of ERK and JNK pathways in IFN-γ-induced B7-DC expression on tumor cells.

Junfang Deng1, Yigang Qian, Lei Geng, Haiyang Xie, Yan Wang, Guoping Jiang, Lin Zhou, Ming Zhang, Shusen Zheng.   

Abstract

PURPOSE: B7-DC on tumor cells was demonstrated to promote tumor immunity; however, the precise mechanism responsible for the aberrant B7-DC expression remains unknown. Interferon gamma (IFN-γ) can induce B7-DC expression on macrophages and has been shown to regulate anti-tumor immunity by various mechanisms. This study was designed to investigate the relationship of IFN-γ and B7-DC on tumor cells and further explored the signal transduction pathways involved.
METHODS: RT-PCR and flow cytometry were used for the analysis of B7-DC expression on various tumor cells. The phosphorylation of p38, ERK1/2, JNK, Akt, and JAK2 was determined by Western blot.
RESULTS: IFN-γ markedly up-regulated B7-DC expression on various tumor cells and resulted in the phosphorylation of JAK2, JNK, ERK, p38, and Akt. Inhibition of ERK or JNK pathway significantly decreased IFN-c-induced B7-DC expression, whereas inhibition of phosphorylation of Akt, p38, and JAK2 had very little effect on IFN-γ-induced B7-DC expression.
CONCLUSIONS: Our findings demonstrate that the pretreatment of tumor cells with IFN-γ enhances B7-DC expression through ERK and JNK pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20390427     DOI: 10.1007/s00432-010-0876-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Stat1-independent regulation of gene expression in response to IFN-gamma.

Authors:  C V Ramana; M P Gil; Y Han; R M Ransohoff; R D Schreiber; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

3.  IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes.

Authors:  Naoko Kanda; Teruo Shimizu; Yayoi Tada; Shinichi Watanabe
Journal:  Eur J Immunol       Date:  2007-02       Impact factor: 5.532

4.  Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.

Authors:  M Sakatsume; L F Stancato; M David; O Silvennoinen; P Saharinen; J Pierce; A C Larner; D S Finbloom
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

5.  Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo.

Authors:  C Sgadari; J M Farber; A L Angiolillo; F Liao; J Teruya-Feldstein; P R Burd; L Yao; G Gupta; C Kanegane; G Tosato
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

Review 6.  Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.

Authors:  Chilakamarti V Ramana; M Pilar Gil; Robert D Schreiber; George R Stark
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

7.  Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs.

Authors:  H Naganuma; A Sasaki; E Satoh; M Nagasaka; S Nakano; S Isoe; H Nukui
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.

Authors:  Shengdian Wang; Jürgen Bajorath; Dallas B Flies; Haidong Dong; Tasuku Honjo; Lieping Chen
Journal:  J Exp Med       Date:  2003-04-28       Impact factor: 14.307

10.  B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Authors:  Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  5 in total

Review 1.  Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Authors:  Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2014-09-12       Impact factor: 5.852

2.  Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.

Authors:  Chun-Yan Wang; Rui Hua; Li Liu; Xiaomin Zhan; Simei Chen; Song Quan; Qing-Jun Chu; Yong-Tong Zhu
Journal:  Cancer Med       Date:  2017-02-16       Impact factor: 4.452

3.  Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway.

Authors:  Runjia Fu; Xiaohong Wang; Ying Hu; Hong Du; Bin Dong; Sheng Ao; Li Zhang; Zhijian Sun; Lianhai Zhang; Guoqing Lv; Jiafu Ji
Journal:  Int J Oncol       Date:  2019-03-12       Impact factor: 5.650

4.  Stanniocalcin-1 Protects a Mouse Model from Renal Ischemia-Reperfusion Injury by Affecting ROS-Mediated Multiple Signaling Pathways.

Authors:  Dajun Liu; Huiping Shang; Ying Liu
Journal:  Int J Mol Sci       Date:  2016-07-12       Impact factor: 5.923

Review 5.  Interferon-Gamma-Mediated Osteoimmunology.

Authors:  Mengjia Tang; Li Tian; Guojing Luo; Xijie Yu
Journal:  Front Immunol       Date:  2018-06-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.